Virally infected hematopoietic cells and uses thereof
AssigneeCelverum Inc.
InventorsDavid Conrad, John Cameron Bell, Harry Atkins
Life of this patent
Estimating the term…
Abstract
An immunogenic formulation for a patient, the formulation includes virus-modulated hematopoietic cancer cells, where the modulated hematopoietic cancer cells are generated from viable hematopoietic cancer cells obtained from the patient, either isolated or in a mixed hematopoietic population of healthy and cancer cells, and where the viable hematopoietic cancer cells are infected ex vivo with a virus that modulates the expression of a plurality of endogenous immune regulatory molecules to increase the immunogenicity of the hematopoietic cancer cells.
Claims17
A method of preparing an immunogenic formulation for treating a patient, the method comprising:
- obtaining uninfected hematopoietic cancer cells from the patient;
- testing and quantifying the uninfected hematopoietic cancer cells from the patient for expression of CD40 on cells;
- infecting, ex-vivo, the obtained uninfected hematopoietic cancer cells with an oncolytic rhabdovirus that modulates the expression of endogenous immune regulatory molecules including CD40 to increase the immunogenicity of the infected hematopoietic cancer cells;
- incubating the infected hematopoietic cancer cells to generate infected hematopoietic cancer cells having increased immunogenicity;
- testing and quantifying the infected hematopoietic cancer cells in the formulation for expression of CD40 on cells;
- and
- formulating the rhabdovirus-infected hematopoietic cancer cells having increased immunogenicity into a formulation wherein, the concentration of infected hematopoietic cancer cells expressing CD40 is greater than the concentration of uninfected hematopoietic cancer cells expressing CD40.
Dependencies are inferred from the claim text.